OBJECTIVES Given the disparity that exists in enrollment of minorities to oncology clinical trials, the objective of our study was to assess whether race is associated with willingness to participate in gynecologic oncology clinical trials in a rural Southern academic medicine setting. Our secondary aim was to determine whether willingness to participate is impacted by an educational intervention. METHODS A single institution prospective survey study was performed at an academic medical center. find more Women presenting to the gynecologic oncology clinic with a current or prior diagnosis of gynecologic malignancy were approached to participate. The validated Attitudes to Randomized Trials Questionnaire (ARTQ) assessed willingness to participate in clinical trials. Relevant demographic and clinical data were abstracted. Characteristics were compared between those willing and unwilling to participate in clinical trials with a chi-square test for categorical variables and Wilcoxon rank sum tests for continuous data. RESUlogy clinical trials. OBJECTIVE Cancer patient-derived organoids (PDOs) grow as three dimensional (3D) structures in the presence of extracellular matrix and have been found to represent the original tumor's genetic complexity. In addition, PDOs can be grown and subjected to drug sensitivity testing in a shorter time course and with lesser expense than patient-derived xenograft models. Many patients with recurrent ovarian cancer develop malignant effusions that become refractory to chemotherapy. Since these same patients often present for palliative aspiration of ascites or pleural effusions, there is a potential opportunity to obtain tumor specimens in the form of multicellular spheroids (MCS) present in malignant effusion fluids. Our objective was to develop a short duration culture of MCS from ovarian cancer malignant effusions in conditions selected to support organoid growth and use them as a platform for empirical drug sensitivity testing. METHODS In this study, malignant effusion specimens were collected from patients with S from HGSOC malignant effusions can be used as a platform for empiric drug sensitivity testing. These ex vivo models may be helpful in screening new or existing therapeutic agents prior to individualized treatment options. We hypothesized that delaying by approximately 12 h the artificial insemination (AI) of heifers with sex-sorted semen increases pregnancy per AI (P/AI). Holstein heifers (n = 1,207) were fitted with a collar containing an automated estrus-detection device (HR-LDn tags, SCR Engineers Ltd., Netanya, Israel) at 10.7 ± 0.02 mo of age. Once they reached 330 kg, heifers were enrolled in an ovulation synchronization protocol (5-d Cosynch + controlled internal drug release; Zoetis, Parsippany-Troy Hills, NJ). Study personnel recorded the heifers that were in estrus according to the DataFlow II software (SCR Engineers Ltd., Netanya, Israel) twice daily at 0500 and 1500 h from the day of the first PGF2α (Estrumate; Merck Animal Health, Madison, NJ) injection to 72 h later. Heifers enrolled in the conventional (CONV) and early sex-sorted (SSEarly) semen treatments detected in estrus at 0500 and 1500 h were AI at 0600 and 1600 h of the same day, respectively. Heifers enrolled in the late sex-sorted (SSLate) semen treatmey (65.8 ± 2.5%) and SSLate (70.0 ± 2.5%) treatments produced a live female calf compared with the CONV treatment (40.5 ± 2.7%). When the values of 1-d-old female and male calves were USD $0 and the cost of replacement heifers was $750, the cost of raising heifers from enrollment to calving was lesser for the CONV treatment than the SSEarly treatment, but SSLate treatment did not differ from CONV and SSEarly treatments. When the values of a 1-d-old female calf ≥$130 and 1-d-old male calf ≥$30 and the cost of replacement ≥$1,000, no differences were observed among treatments in the cost from enrollment to calving. We conclude from this experiment that the P/AI with sex-sorted semen is not improved when insemination is delayed by approximately 12 h. We evaluated the effects of commercially available fatty acid (FA) supplements containing palmitic (C160) and stearic acid (C180) on nutrient digestibility and production responses of dairy cows. Thirty-six mid-lactation (146 ± 55 d in milk) multiparous Holstein cows were randomly assigned to twelve 3 × 3 balanced truncated Latin squares, with 3 treatments and 2 consecutive 35-d periods, with the final 5 d used for sample and data collection. Treatments were (1) a control diet containing no supplemental FA (CON), (2) a control diet supplemented with a commercially available C160 supplement (PA), and (3) a control diet supplemented with a commercially available C160 and C180 supplement (MIX). Supplements were fed at 1.5% dry matter and replaced soyhulls in CON. The statistical model included the random effect of cow nested within square and the fixed effects of treatment, period, square, and their interactions. Preplanned contrasts were (1) overall effect of FA treatments [CON vs. the average of the FA treatme of milk respond better to a FA supplement enriched in C160 compared with a supplement containing both C160 and C180, which is likely due in part to PA increasing FA and neutral detergent fiber digestibility compared with MIX. The objective of this study was to investigate the effects of an enzymatically hydrolyzed cottonseed protein (HCSP) as a peptide source on performance, blood metabolites, gastrointestinal development, and intestinal microbes. Forty-eight newborn Holstein calves were randomly assigned to 1 of the 4 dietary treatments including 0, 2, 4, and 6% of HCSP (dry matter basis). All calves received the same amount of pasteurized whole milk, weaned on d 56 of the experiment, and the study was concluded on d 70. Data were analyzed using PROC MIXED in SAS (SAS Institute Inc., Cary, NC) as a randomized complete block design with linear and quadratic contrasts. Results showed that increased amount of HCSP linearly decreased the starter intake during the postweaning (d 57 to 70) and overall period (d 1 to 70). In addition, when dietary HCSP increased during the overall period, average daily gain tended to linearly decrease. All skeletal growth variables also linearly decreased as dietary HCSP increased at the end of the study, except for body length, which did not differ among the treatments.